Quick takeaways
- CRISPR is moving from a lab idea toward real treatments, but it is not universal medicine.
- Editing blood cells is very different from safely editing organs inside the body.
- An edit has to work in the right cells and remain safe enough to use.
In December 2023, the FDA approved Casgevy for sickle cell disease. It was the first U.S. approval for a treatment built with CRISPR. In the trial behind the decision, 29 of the 31 evaluable patients avoided severe pain crises for at least twelve consecutive months.
The result covers 29 of 31 evaluable patients. The treatment also costs $2.2 million before the hospital process around it, which can keep an effective gene edit out of reach.
First, what CRISPR is. DNA is a four-letter code, billions of letters long, and every cell carries the full sequence. CRISPR is a system that bacteria evolved to defend against viruses. Researchers figured out how to repurpose it as a set of molecular scissors. You design a short RNA sequence that matches the stretch of DNA you want to cut, attach it to the Cas9 protein, and it finds that specific sequence and cuts it. Then the cell's repair machinery takes over, either disabling the gene or replacing it with a corrected version.
The system is programmable. Researchers can change the target by changing the guide RNA, usually much faster than developing a new therapy platform from scratch.
Other teams are testing edits for beta thalassemia, inherited blindness and some cancers. An early transthyretin-amyloidosis trial showed that an edit delivered inside the body could sharply reduce the disease-related protein. That is a different problem from removing blood stem cells, editing them in a lab and returning them to the patient.
The old worry is still there: off-target cuts, where the scissors edit a part of the genome they were not supposed to reach. Researchers have built more precise delivery systems and more accurate Cas variants, but the risk has not gone away.
Germline editing generates the most heated debate. In 2018, a Chinese researcher named He Jiankui edited human embryos that were subsequently implanted and born, creating the first humans with heritable CRISPR edits. He was imprisoned. The scientific consensus remains that heritable human editing is not ready for clinical use, and most countries lack the oversight framework such work would require.
CRISPR now has an approved treatment. I want the next studies to show which patients can reach it, which organs can be edited safely, and how doctors will detect a rare off-target change years later.
Delivery decides what can be edited
Casgevy works with blood stem cells that doctors can remove, edit in a lab and check before returning them. Editing cells deep inside the brain or heart is harder because the treatment has to reach the right cells without affecting the wrong ones.
That makes delivery part of the therapy itself. A precise editor is only useful if it arrives at the intended tissue in a safe dose.
I expect the next CRISPR breakthroughs to be narrow solutions, each disease bringing its own target and its own delivery problem.